BioMark Diagnostics Inc
Research BioMark Diagnostics Inc (20B) on Bullrun: market cap EUR 33.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker20B
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 33.42M
- Financial periodQ4 2025
- RevenueEUR 6.92K
- Net income-EUR 380.32K
- Free cash flow-EUR 818.96K
Valuation Snapshot
latest market cap is EUR 33.42M.
About BioMark Diagnostics Inc
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers.
Frequently asked questions
What is BioMark Diagnostics Inc's market cap?
BioMark Diagnostics Inc's market capitalization is EUR 33.42M.
What does BioMark Diagnostics Inc do?
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck...